Document is current
Any future updates will be listed below
-
Authors
Khwaja, Jahanzaib https://orcid.org/0000-0002-4993-7828
Bomsztyk, Joshua
Mahmood, Shameem
Wisniowski, Brendan
Shah, Raakhee
Tailor, Anish
Yong, Kwee https://orcid.org/0000-0002-6487-276X
Popat, Rakesh
Rabin, Neil
Kyriakou, Charalampia
Sive, Jonathan
Esposti, Simona Degli
Larkin, Daniel F. P. https://orcid.org/0000-0003-2506-0280
Worthington, Sarah
Hart, Alyse
Dowling, Emma
Correia, Nuno
Bygrave, Ceri
Rydzewski, Andrzej https://orcid.org/0000-0002-6330-1789
Jamroziak, Krzysztof
Wechalekar, Ashutosh D. https://orcid.org/0000-0002-4406-7237
- License Information
-
More Information
Article History
Received: 27 June 2022
Revised: 26 July 2022
Accepted: 2 August 2022
First Online: 5 September 2022
Competing interests
: JK, JB, SM, BW, RS, AT, CK, JS, SDE, DFPL, SW, AH, ED, NC, CB, KJ: no conflict of interest. KY: BMS research funding; Amgen honoraria; GSK honoraria; Takeda honoraria; Janssen honoraria, research funding; Sanofi honoraria, research funding; Autolus research funding. RP: AbbVie, BMS, Janssen, Oncopeptides, and Amgen honoraria; Takeda honoraria; GlaxoSmithKline consultancy, honoraria, research funding; Abbvie, Takeda, Janssen, and Celgene consultancy; Janssen and BMS travel expenses; NR: BMS/Celgene consultancy, honoraria, travel support for meetings; Takeda consultancy, honoraria, travel support for meetings; Janssen: consultancy, honoraria, travel support for meetings; AR: honoraria (for invited lectures) and travel grants Astellas, Fresenius, Sandoz; ADW: Amgen research funding; Alexion, AstraZeneca rare disease consultancy; Caelum Biosciences: clinical trial funding; Janssen consultancy; Takeda honoraria; Celgene honoraria.
